Soru

Zorluk: ZorPharmacokinetic and Pharmacodynamic Principles

A clinical pharmacologist is reviewing medication management protocols for a hospital system. Various clinical interventions and patient-specific factors necessitate adjustments in pharmacotherapy based on underlying pharmacokinetic principles. Match each clinical scenario or intervention on the left with its most accurate expected pharmacokinetic consequence on the right.

  • Initiating intermittent hemodialysis for a patient on a medication with a volume of distribution (VdV_d) of 15 L/kg15 \text{ L/kg} and 98% plasma protein binding.Minimal increase in total extracorporeal clearance; supplemental post-procedural dosing is generally unnecessary.
  • Doubling the continuous intravenous infusion rate of a medication that exhibits strict first-order elimination kinetics.The steady-state plasma concentration precisely doubles, but the time required to achieve this new steady state remains unchanged.
  • Converting a medication known to undergo extensive hepatic first-pass metabolism from an oral formulation to a sublingual formulation.Substantial increase in systemic bioavailability (FF), necessitating a lower administered dose to achieve the same target serum concentration.
  • Increasing the daily maintenance dose by 20% for a medication that strictly follows zero-order (capacity-limited) elimination kinetics.A disproportionate, non-linear elevation in steady-state plasma concentration, significantly increasing the risk of dose-dependent toxicity.

Cevap

The clinical interventions dictate specific pharmacokinetic outcomes: high VdV_d and high protein binding preclude hemodialysis clearance; first-order infusions alter CssC_{ss} but not the time to steady state; sublingual dosing bypasses first-pass metabolism to increase FF; and zero-order drugs accumulate disproportionately with any dose increases.
Each clinical scenario strictly aligns with fundamental pharmacokinetic rules. High volume of distribution and extensive protein binding severely limit a drug's presence in the dialyzable plasma compartment. Sublingual dosing alters the anatomical absorption route to bypass hepatic enzymes, massively increasing bioavailability. First-order kinetics maintain a constant half-life, meaning time to steady state is unaffected by dose rate changes, whereas zero-order kinetics involve saturated enzymes that cannot accommodate dose increases proportionally.

Adım Adım Çözüm

1
Analyze the effect of hemodialysis on a drug with a VdV_d of 15 L/kg15 \text{ L/kg} and 98% protein binding.
The drug is determined to be poorly dialyzable.
High VdV_d indicates extensive tissue distribution, and high protein binding keeps the small intravascular fraction trapped. Hemodialysis only effectively removes unbound, free drug present in the plasma compartment.
2
Evaluate the pharmacokinetic impact of doubling an IV infusion rate for a first-order drug.
Steady-state concentration (CssC_{ss}) doubles, but the time to CssC_{ss} is unchanged.
First-order kinetics dictate a linear relationship between infusion rate and CssC_{ss} (Css=RateClC_{ss} = \frac{\text{Rate}}{Cl}). Time to steady state depends solely on the half-life (requiring 4-5 half-lives), which does not fluctuate with dose.
3
Determine the physiological consequence of switching a high first-pass drug to sublingual administration.
Systemic bioavailability (FF) increases dramatically.
Sublingual venous drainage bypasses the portal vein, avoiding initial hepatic enzymatic degradation and allowing the full active dose to enter the systemic circulation.
4
Assess the effect of a 20% dose increase on a zero-order elimination drug.
Disproportionate, exponential increase in steady-state concentration.
Because elimination pathways are fully saturated, any additional drug administered cannot be cleared at a proportional rate, leading to non-linear and potentially toxic accumulation.

Anahtar Kavram

Clinical pharmacokinetics: dialyzability, infusion kinetics, first-pass metabolism, and capacity-limited elimination.
Bu soruyu puanla